Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049662 | 0.92 | KCNH2 (0.62) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL2068425 | 0.90 | KCNH2 (0.59) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL2068859 | 0.88 | KCNH2 (0.55) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL997924 | 0.87 | KCNH2 (0.64) | KCNH2PABPC1CTSSCTSKSCN9A | |
| SCHEMBL20121537 | 0.85 | KCNH2 (0.53) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL2068538 | 0.84 | KCNH2 (0.54) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL18136313 | 0.84 | KCNH2 (0.58) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL1051096 | 0.83 | KCNH2 (0.58) | KCNH2PABPC1P2RX7CTSSCTSK | |
| SCHEMBL2068519 | 0.83 | KCNH2 (0.59) | KCNH2PABPC1CTSSCTSKSCN9A | |
| SCHEMBL2069062 | 0.83 | KCNH2 (0.51) | KCNH2PABPC1P2RX7CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | SQLE, SGMS2, SGMS1 | KCNH2 1904/4885PABPC1 4699/4885P2RX7 1086/4885 |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, ABCB1, FDPS | KCNH2 1679/4885PABPC1 4650/4885P2RX7 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.